Andrew K. Rooke Net Worth

The estimated Net Worth of Andrew K. Rooke is at least $4.15 Million dollars as of 13 June 2014. Andrew Rooke owns over 30,000 units of ClearPoint Neuro Inc stock worth over $4,152,645 and over the last 11 years Andrew sold CLPT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Andrew Rooke CLPT stock SEC Form 4 insiders trading

Andrew has made over 2 trades of the ClearPoint Neuro Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Andrew bought 30,000 units of CLPT stock worth $21,900 on 13 June 2014.

The largest trade Andrew's ever made was buying 50,000 units of ClearPoint Neuro Inc stock on 10 June 2014 worth over $39,000. On average, Andrew trades about 3,077 units every 0 days since 2013. As of 13 June 2014 Andrew still owns at least 340,102 units of ClearPoint Neuro Inc stock.

You can see the complete history of Andrew Rooke stock trades at the bottom of the page.

What's Andrew Rooke's mailing address?

Andrew's mailing address filed with the SEC is C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE,, CA, 92618.

Insiders trading at ClearPoint Neuro Inc

Over the last 13 years, insiders at ClearPoint Neuro Inc have traded over $1,109,516 worth of ClearPoint Neuro Inc stock and bought 529,405 units worth $775,964 . The most active insiders traders include Lynnette C Fallon, Michael Pietrangelo, and R John Fletcher. On average, ClearPoint Neuro Inc executives and independent directors trade stock every 93 days with the average trade being worth of $207,411. The most recent stock trade was executed by Lynnette C Fallon on 14 May 2024, trading 17,153 units of CLPT stock currently worth $209,438.

What does ClearPoint Neuro Inc do?

we are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot

Complete history of Andrew Rooke stock trades at ClearPoint Neuro Inc

ClearPoint Neuro Inc executives and stock owners

ClearPoint Neuro Inc executives and other stock owners filed with the SEC include:

• Joseph Michael Burnett,
  Pres, CEO & Director
• Danilo D'Alessandro,
  Chief Financial Officer
• Peter G. Piferi,
  Chief Operating Officer
• Mazin Sabra,
  Chief Operating Officer
• Dr. Paul A. Bottomley,
  Advisor
• Jacqueline Keller,
  VP of Marketing
• Ellisa Cholapranee,
  Gen. Counsel
• Mazin Sabra,
  Chief Operating Officer
• Linda M. Liau,
  Director
• Matthew B. Klein,
  Director
• Harold A Hurwitz,
  Chief Financial Officer
• Peter G. Piferi,
  Chief Operating Officer
• Charles E Koob,
  Director
• Michael Pietrangelo,
  Director
• Kimble L. Jenkins,
  Director
• John N Jr Spencer,
  Director
• Pascal E R Girin,
  Director
• Timothy T. Richards,
  Director
• R John Fletcher,
  Director
• Maria Sainz,
  Director
• Philip A. Pizzo,
  Director
• Joseph Michael Burnett,
  CEO and President
• Wendelin C Maners,
  Vice President, Marketing
• Michael J. Ryan,
  Director
• Robert C. Korn,
  VP, Global Sales & Marketing
• Andrew K. Rooke,
  Director
• James K. Jr. Malernee,
  Director
• Paul A. Bottomley,
  Director
• David W. Carlson,
  Chief Financial Officer
• Oscar L. Thomas,
  V.P., Business Affairs
• Bruce C. Conway,
  Director
• Francis P Grillo,
  CHIEF EXECUTIVE OFFICER
• B Kristine Johnson,
  Director
• Danilo D'alessandro,
  Chief Financial Officer
• Lynnette C Fallon,
  Director
• L. Jeremy Stigall,
  Chief Business Officer